Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model

Oligonucleotides

Volumn 17, Issue 1, 2007, Pages 22-34

  Chaturvedi, Anuhar ^a   Battmer, Karin ^a   Schaefer, Daniel ^a   Ganser, Arnold ^a   Eder, Matthias ^a   Scherr, Michaela ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CYTARABINE; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; GENE PRODUCT; IMATINIB; INTERLEUKIN 3; PROTEIN GAB2; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; SHORT HAIRPIN RNA; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; COMBINATORIAL LIBRARY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SPECIFICITY; GENE EXPRESSION; GENE TARGETING; IC 50; LENTIVIRINAE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TARGETING; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; GENE THERAPY; INHIBITORY CONCENTRATION 50; INTERLEUKIN-3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LENTIVIRUS; LEUKEMIA, MYELOID, CHRONIC; MICE; MODELS, BIOLOGICAL; PHOSPHOPROTEINS; PIPERAZINES; PROTEIN-TYROSINE-PHOSPHATASE; PYRIMIDINES; RNA INTERFERENCE; RNA, SMALL INTERFERING; STAT5 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

LENTIVIRUS;

EID: 34247487369     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2006.0054     Document Type: Article

References (32)

1. COPLAND, M., HAMILTON, A., ELRICK, L.J., BAIRD, J.W,. ALLAN, E.K., JORDANIDES, N., BAROW, M., MOUNTFORD, J.C., and HOLYOAKE, T.L. (2006). Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 107, 4532-4539.
2. DEININGER, M., BUCHDUNGER, E., and DRUKER, B.J. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-2653.
3. DRUKER, B.J. (2004). Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 91, 1-30.
4. DRUKER, B. (2005). The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105, 2640-2653.
5. FANG, G., KIM, C., PERKINS, C., RAMADEVI, N., WINTON, E., WITTMANN, S., and BHALLA, K.N. (2000). CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes BCR-ABL-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96, 2246-2253.
6. GOTLIB, J. (2005). Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. Curr. Hematol. Rep. 4, 77-84.
7. GU, H., PRATT, J.C., BURAKOFF, S.J., and NEEL, B.G. (1998). Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol. Cell. 2, 729-740.
8. GUO, F., SIGUA, C., BALI, P., GEORGE, P., FISKUS, W., SCUTO, A. ANNAVARAPU, S., MOUTTAKI, A., SONDARVA, G., WEI, S., WU, J., DJEU, J., and BHALLA, K. (2005). Mechanistic role of heat shock protein 70 in BCR-ABL-mediated resistance to apoptosis in human acute leukemia cells. Blood 105, 1246-1255.
9. HAHN, O., and STADLER, W. (2006). Sorafenib. Curr. Opin. Oncol. 18, 615-621.
10. KANO, Y., AKUTSU, M., TSUNODA, S., MANO, H., SATO, Y., HONMA, Y., and FURUKAWA, Y. (2001). In vitro cytotoxic effects of a tyrosine kinase inhibitor ST1571 in combination with commonly used antileukemic agents. Blood 97, 1999-2007.
11. KINDLER, T., BREITENBUECHER, F., KASPER, S., STEVENS, T., CARIUS, B., GSCHAIDMEIER, H., HUBER, C., and FISCHER T. (2003). In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia 17, 999-1009.
12. KLUCHER, K.M., LOPEZ, D.V., and DALEY, G.Q. (1998). Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood 91, 3927-3934.
13. KOYAMA, N., KOSCHMIEDER, S., TYAGI, S., PORTEROROBLES, I., CHROMIC, J., MYLOCH, S. NURNBERGER, H,. ROSSMANITH, T., HOFMANN, W.K., HOELZER, D., and OTTMANN, O.G. (2006). Inhibition of phosphotyrosine phosphatase IB causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571. Clin. Cancer. Res. 12, 2025-2031.
14. LEVY, D.E., and DARNELL, J.E. Jr. (2002). Stats: transcriptional control and biological impact. Nature Rev. Mol. Cell Biol. 3, 651-662.
15. LIU, W., STIMSON, L., and JOEL, S. (2002). The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukemia cells: synergistic interactions with anti-leukemic agents. Br. J Cancer 86, 1472-1478.
16. MANNEN, J.V., RETEL, J., VRIES, J.D., and PINEDO, H. (1998). Mechanism of action of drug etoposide:a review. J. Natl. Cancer Inst. 80, 1526-1533.
17. NEEL, B., GU, H., and PAO, L. (2003): The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28, 284-293.
18. OSHEROFF, N., CORBETT, A., and ROBINSON, M. (1994). Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv. Pharmacol. 29B, 105-126.
19. PATEL, P.H., CHAGANTI, R.S., and MOTZER, R.J. (2006). Targeted therapy for metastatic renal cell carcinoma. Br. J. Cancer 13, 614-619.
20. REN, R. (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia. Nature Rev. Cancer 5, 172-183.
21. SATTLER, M., MOHI, M.G., PRIDE, Y.B., QUINNAN, L.R., MALOUF, N.A., PODAR, K. GESBERT, F., IWASAKI, H., LI, S., VAN ETTEN, R.A., GU, H., GRIFFIN, J.D., and NEEL, B.G. (2002). Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1, 479-492.
22. SCHERR, M., BATTMER, K., GANSER, A., and EDER, M. (2003). Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle 2, 251-257.
23. SCHERR, M., BATTMER, K., SCHULTHEIS, B., GANSER, A., and EDER, M. (2005). Stable RNA interference (RNAi) as an option for anti-BCR-ABL therapy. Gene Ther. 12, 12-21.
24. SCHERR, M., CHATURVEDI, A., BATTMER, K., DALLMANN, I., SCHULTHEIS, B., GANSER, A, and EDER, M. (2006). Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 107, 3279-3287.
25. SHAH, N., TRAN, C., LEE, F., CHEN, P., NORRIS, D., and SAWYERS, C. (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401.
26. TAUCHI, T., and OHYASHIKI, K. (2006). The second generation of BCR-ABL tyrosine kinase inhibitors. Int. J. Hematol. 83, 294-300.
27. TOPALY, J., ZELLER, W., and FRUEHAUF, S. (2001). Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15, 342-347.
28. von BUBNOFF, N., VEACH, D.R., VAN DER KUIP, H., AULITZKY, W.E., SANGER, J., SEIPEL, P., BORNMANN ,W.G., PESCHEL, C., CLARKSON, B., and DUYSTER, J. (2005). A cell-based screen for resistance of BCR-ABL-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 105, 1652-1659.
29. WEISBERG, E., MANLEY, P., BREITENSTEIN, W., BRUGGEN, J., COWAN-JACOB, S., RAY, A., HUNTLY, B., FABBRO, D., FENDRICH, G., HALL-MEYERS, E., KUNG, A.L., MESTAN, J., DALEY, G.Q., CALLAHAN, L., CATLEY, L., CAVAZZA, C., AZAM, M., NEUBERG, D., WRIGHT, R.D., GILLILAND, D.G., and GRIFFIN, J.D. (2005). Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell 7, 129-141.
30. WOHLBOLD, L., van der KUIP, H., MIETHING, C., VORNLOCHER, H.P., KNABBE, C., DUYSTER, J., and AULITZKY, W.E. (2003). Inhibition of BCR-ABL gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102, 2236-2239.
31. YAO, Y.L., and YANG, W.M. (2005). Nuclear proteins: promising targets for cancer drugs. Curr Cancer Drug Targets 5, 595-610.
32. YE, D., WOLFF, N., LI, L., ZHANG, S., and ILARIA, R.L. JR. (2006). STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 107, 4917-4925.